| abstract |
The present invention relates to a composition for diagnosing liver cancer containing TM7SF3 as an active ingredient, a kit for diagnosing liver cancer with anti-TM7SF3 antibodies as reagent, and a pharmaceutical composition for preventing or treating liver cancer containing the anti-TM7SF3 antibodies as an active ingredient. The TM7SF3 protein is rarely expressed in liver tissue of a healthy person, but is specifically over-expressed in malignant hepatic tissue of liver cancer patients. As diagnosis or prognosis of liver cancer is thus predictable, the TM7SF protein can be used as a marker for diagnosing liver cancer. In addition, the anti-TM7SE3 antibodies of the present invention specifically bind with an extracellular domain of the TTM7SF3, and respond to this particular liver cell line. Therefore, the anti-TM7SE3 antibodies selectively induce apoptosis of only cancer cells caused by IM7SF3 over-expression, and can thus be used in preventing or treating liver cancer. |